Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
50,830
Total Claims
$2.9M
Drug Cost
2,050
Beneficiaries
$1,410
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
+25%
Cost per patient vs peers
$1,410 vs $1,128 avg
+28%
Brand preference vs peers
10.7% vs 8.4% avg
Brand vs Generic
Brand: 5,390 claims · $2.1M
Generic: 44,823 claims · $759K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 284 | $209K |
| Sitagliptin Phos/Metformin Hcl | 156 | $178K |
| Linagliptin | 171 | $169K |
| Insulin Glargine,hum.Rec.Anlog | 233 | $149K |
| Dapagliflozin Propanediol | 118 | $145K |
| Rivaroxaban | 157 | $127K |
| Levothyroxine Sodium | 1,557 | $102K |
| Insulin Nph Hum/Reg Insulin Hm | 173 | $94K |
| Sitagliptin Phosphate | 48 | $67K |
| Linagliptin/Metformin Hcl | 47 | $67K |
| Insulin Lispro | 61 | $55K |
| Ticagrelor | 90 | $51K |
| Atorvastatin Calcium | 2,693 | $42K |
| Dulaglutide | 40 | $41K |
| Empagliflozin | 25 | $40K |
Prescribing Profile
Patient Profile
75
Avg Age
60%
Female
2.78
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data